Prof. Mehdi Hamadani
West Virginia
University, USA
Email: mehdi.hamadani@gmail.com
Qualifications
1995 M.Sc., King Edward Medical College
1993 B.Sc., Government College
Publications (selected)
-
Pant S.,
Hamadani M., Dodds AJ., Szer J., Crilley PA., Stevenson D., Phillips G., Elder
P, Nivison-Smith I, Avalos BR., Penza S., Topolsky D., Sobecks R., Kalaycio M.,
Bolwell BJ., Copelan EA.: “Incidence and reasons for late failure after
allogeneic hematopoietic cell transplantation following BuCy2 in acute myeloid
leukemia.” Br J Haematol. 2010 February;148(4):623-626. Epub 2009 October 11.
-
Benson DM Jr.,
Panzner K., Hamadani M., Hofmeister CC., Bakan CE., Smith MK., Elder P., Krugh
D., O’Donnell L., and Devine SM.: “Effects of induction with novel agents
versus conventional chemotherapy on mobilization and autologous stem cell
transplant outcomes in multiple myeloma.” Leuk Lymphoma. 2010
Februrary;51(2):243-251. Epub 2009 December 28.
-
Hamadani M.,
Awan FT.: "Remission induction, consolidation and novel agents in
development for adults with acute myeloid leukemia." Hematol Oncol. 2010
March;28(1):3-12. Epub 2009 July 31.
-
Christian B.,
Zhao W., Hamadani M., Sotomayor, EM., Narvarro W., Devine SM., Racke F., Blum
KA.: “Mantle cell lymphoma twelve years after allogeneic bone marrow transplant
occurring simultaneously in recipient and donor.” J Clin Oncol. 2010
November;28(31):e629-632. Epub 2010 Aug 23.
-
Hamadani M.,
Craig M., Awan FT., Devine SM.: “How we approach patient evaluation for
hematopoietic stem cell transplantation.” Bone Marrow Transplant. 2010
August;45(8):1259-1268. Epub 2010 May 17.
-
Awan FT.,
Osman S., Kochuparambil ST., Gibson L., Remick SC., Abraham J., Craig M.,
Jillella A., Hamadani M.: “Impact of response to thalidomide, lenalidomide or
bortezomib containing induction therapy on the outcomes of multiple myeloma
patients undergoing autologous transplantation.” Bone Marrow Transplant. 2012
January;47(1):146-148. Epub 2011 Feb 28.
-
Hamadani M.,
Craig M., Phillips G., Abraham J., Tse W., Cumpston C., Gibson L., Remick S.,
Hofmeister C., Penza S., Efebera Y., Andritsos L., Garzon R., Benson D., Blum
W., Devine SM.: “Higher busulfan dose intensity does not improve outcomes of
patients undergoing allogeneic hematopoietic cell transplantation following
fludarabine, busulfan-based reduced toxicity conditioning.” Hematol Oncol. 2011
December;29(4):202-210. Epub 2011 Feb 28.
-
Hamadani M.,
Craig M., Gibson L., Remick S.: “The evolving role of statins in hematopoietic
stem and progenitor cell transplantation.” Am J Blood Res. 2011
June;1(1):57-64.
-
Kumar S.,
Zhang M., Li P., Dispenzieri A., Milone G., Lonial S., Krishnan A., Maiolino
A., Wirk B., Weiss B., Freytes C., Vogl D., Vesole D., Lazarus H., Meehan K.,
Hamadani M., Lill M., Callander N., Majhail N., Wiernik P., Nath R., Kamble R.,
Vij R., Kyle R., Gale R., Hari P.: “Trends in allogeneic stem cell
transplantation for multiple myeloma: a center for international blood and
marrow transplant research (CIBMTR) analysis.” Blood. 2011 Aug;118(7)1979-1988.
Epub 2011 Jun 20.
-
Liu K.,
Anthony BA., Liu K., Yearsly MM., Hamadani M., Devine SM., Hadley GA.: “CD103
deficiency prevents graft-versus-host disease but spares graft-versus-tumor
effects mediated by alloreactive CD8 T cells.” PLoS One. 2011;6(7): e21968.
Epub 2011 Jul 14.
-
Kanate AS.,
Craig M., Cumpston A., Saad A., Hobbs G., Leadmon S., Bunner P., Watkins K.,
Bulian D., Gibson L., Abraham J., Remick SC., Hamadani M.: “Higher infused
CD34+ cell dose and overall survival in patients undergoing in vivo T-cell
depleted, but not T-cell replete allogeneic peripheral blood hematopoietic cell
transplantation.” Hematol Oncol Stem Cell Ther. 2011;4(4):149-156.
-
Hamadani M.,
Kochuparambil ST., Osman S., Cumpston A., Leadmon S., Bunner P., Watkins K.,
Morrison D., Speir E., DeRemer D., Kota V., Jillella A., Craig M., Awan F.:
“Intermediate- versus low-dose cyclophosphamide and granulocyte colony
stimulating factor for peripheral blood stem cell mobilization in multiple
myeloma patients treated with novel induction therapies.” Biol Blood Marrow
Transplant. 2012 Jul;18(7)1128-1135. Epub 2012 Jan 13.
-
Sweet M.,
Cumpston C., Briggs F., Craig M., Hamadani M.: “Impact of alcohol impregnated
port protectors and needleless neutral pressure connectors on central
line-associated blood stream infections and contamination of blood cultures in
an inpatient hematology and oncology unit.” Am J Infect Control. Epub 2012 May
8.
-
Awan F.,
Kochuparambil ST., DeRemer D., Cumpston A., Craig M., Jillella A., Hamadani M.:
"Plerixafor salvage is safe and effective in hard-to-mobilize patients
undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell
mobilization." J Oncol. 2012;2012: 931071. Epub 2012 Apr 10.
-
Ranganathan
P., Heaphy C., Costinean S., Stauffer N., Na C., Hamadani M., Santhanam R., Mao
C., Taylor P., Sandhu S., He G., Shana'ah A., Nuovo G., Obad S., Broom O.,
Kauppinen S., Byrd JC.,
-
Caligiuri M.,
Perotti D., Hadley G., Marcucci G., Devine M., Blazar B., Croce C., Garzon R.:
“Regulation of acute graft-versus-host disease by microRNA-155.” Blood. 2012
May;119(20)4786-4797. Epub 2012 Mar 9.
-
Ballen KK.,
Woolfrey A., Zhu X, Ahn K., Wirk B., Arora M., George B., Savani B., Bolwell
B., Porter D., Copelan E., Hale G., Schouten H., Lewis I., Cahn J., Halter J.,
Cortes J., Kalaycio M., Antin J., Aljurf M., Carabasi M., Hamadani M., McCarthy
P., Pavletic S., Gupta V., Deeg H., Maziarz R., Horowitz M., Saber W.:
“Allogeneic hematopoietic cell transplantation for advanced polycythemia vera
and essential thrombocythemia.” Biol Blood Marrow Transplant. In Press. Epub
2012 Mar 23.
-
Hamadani M.,
Devine SM.: “Patient evaluation before transplantation (adult).” In: Wingard
JR, Gastineau D, Leather H, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic
Stem Cell Transplantation: A Handbook for Clinicians, 1st ed. Bethesda, MD:
AABB Press; 2009: 27-43.